NASDAQ · COOHealthcareOphthalmic Goods

The Cooper Companies financials

$56.63+0.11%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ3 '26
Jul 31
Q2 '26
Apr 30
Q1 '26
Jan 31
Q4 '25
Oct 31
Q3 '25
Jul 31
Q2 '25
Apr 30
Q1 '25
Jan 31
Q4 '24
Oct 31
Q3 '24
Jul 31
Q1 '25
May 4
Q2 '24
Apr 30
Q4 '24
Feb 3
Revenue$1.07B$1.08B$1.02B$1.07B$1.06B$1.00B$964.7M$1.02B$1.00B$746.6M$942.6M$754.3M
Gross profit$711.9M$735.4M$695.2M$650.8M$692.0M$679.1M$660.2M$677.7M$663.0M$330.0M$631.2M$556.5M
Gross margin66.8%68.0%67.9%61.1%65.3%67.8%68.4%66.5%66.1%44.2%67.0%73.8%
Operating income$222.0M-$31.0M$212.8M$140.4M$175.7M$184.8M$182.0M$198.4M$192.5M$6.5M$161.7M-$33.6M
Net income$432.8M-$77.9M$130.8M$84.6M$98.3M$87.7M$104.3M$117.5M$104.7M$783.0K$88.9M-$29.7M
Net margin40.6%−7.2%12.8%7.9%9.3%8.7%10.8%11.5%10.4%0.1%9.4%−3.9%
Diluted EPS$2.24$-0.40$0.66$0.43$0.49$0.44$0.52$0.59$0.52$0.01$0.44$-0.51
EBITDA$316.7M$64.4M$308.3M$238.8M$271.1M$277.4M$273.0M$289.4M$281.5M$22.9M$260.0M-$34.3M
Operating cash flow$341.7M$182.8M$260.9M$247.9M$261.4M$96.2M$190.6M$268.1M$207.5M-$19.7M$111.0M-$40.1M
Free cash flow$273.0M$96.4M$158.7M$149.9M$164.5M$18.1M$101.2M$128.1M$118.5M-$35.6M$36.9M-$52.8M
Diluted shares193.4M195.0M196.7M198.1M200.0M200.7M201.2M200.6M200.6M59.5M200.5M58.1M

Balance sheet

Period endJul 31Apr 30Jan 31Oct 31Jul 31Apr 30
Cash & equivalents$154.7M$138.8M$124.9M$110.6M$124.9M$116.2M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$2.54B$2.46B$2.50B$2.51B$2.48B$2.59B
Total assets$12.67B$12.48B$12.42B$12.39B$12.38B$12.41B
Total liabilities$4.34B$4.24B$4.06B$4.16B$4.02B$4.13B
Shareholders' equity$8.33B$8.24B$8.36B$8.24B$8.35B$8.29B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology